Area:
Visual perception / Memory / Neuroimaging
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Yang Jiang is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2018 |
Jiang, Yang |
R56Activity Code Description: To provide limited interim research support based on the merit of a pending R01 application while applicant gathers additional data to revise a new or competing renewal application. This grant will underwrite highly meritorious applications that if given the opportunity to revise their application could meet IC recommended standards and would be missed opportunities if not funded. Interim funded ends when the applicant succeeds in obtaining an R01 or other competing award built on the R56 grant. These awards are not renewable. |
Predictive Neurophysiological Biomarkers For Risk of Alzheimer?S Disease (Ad) and Related Dementia (Adrd) Induced Cognitive Impairment in Sino-Us Cohorts
ABSTRACT Alzheimer?s disease (AD) and related dementia (ADRD) are irreversible, progressive brain disorders that slowly destroy memory, thinking, and other neuro-cognitive skills in older adults. More people die from ADRD in the US than breast and prostate cancer combined. Medical care for about 50 million ADRD cases worldwide is an enormous financial burden, equivalent to the 18th largest economy in the world. A major challenge for countries like China is that with industrialization and rapid growth of the economy, the prevalence of unhealthy lifestyle and metabolic factors has increased, which contributes to an increased rate of ADRD. Chinese have a much higher risk of stroke and diabetes than Americans, and these traits have not been well-studied in connection with ADRD. Predictive and affordable biomarkers for ADRD risk are needed to tackle dementia in in low- and middle-income regions. The goal of this Sino-US study is to validate neurophysiological biomarkers for individualized prediction of MCI in Kentucky and Beijing cohorts using an ultimate clinical outcome measure, conversion to mild cognitive impairment (MCI), an early stage of ADRD. The cross-national research team will test the central hypothesis that healthy older individuals who have MCI-like neurophysiological brain signatures have high-risk of MCI conversion induced by ADRD. The hypothesis is based on promising results from our longitudinal pilot study, i.e. individuals who convert to MCI have MCI-like brainwave signatures about 5 years before conversion. The team has previously identified unique brainwaves during the Bluegrass memory task in patients with amnestic MCI (aMCI; memory-related impairment) using the Kentucky cohort. Here, matching standardized protocols will be applied in the two Sino & US cohorts. The NIA-funded University of Kentucky Alzheimer?s Disease Center has been following a cohort of 500 cognitively intact older adults to autopsy for the past 35 years, along with multiple ADRD biomarker banks. The Beijing cohort is part of a national longitudinal cohort for ADRD early detection. Specifically, Aim 1 will determine whether individual baseline memory-related neuromarkers are predictors for MCI conversion. Neurocognitive measures will be collected at the baseline and 3-year follow-up in both healthy cohorts to test the hypothesis that the converters to MCI already show abnormality of brain activity patterns at the baseline. Aim 2 will determine whether the neuromarkers differentiate between amnestic versus non-amnestic MCI. The hypothesis that the distinct neurophysiological responses are associated with vascular diseases induced MCI will be tested. Aim 3 will validate the neuromarkers by correlating them with established ADRD biomarkers, and neuropsychological scores from baseline to follow-up. Using gold-standard AD biomarkers, the hypothesis that individuals who are Aß-positive have an increased rate of longitudinal change in neurophysiological biomarkers. These noninvasive and affordable risk markers, once validated and replicated, will be suitable for large-scale use. The propose study will build a base for research networking that can be used for future prevention and treatment.
|
1 |